{
  "client_id": "lai_weekly_v3",
  "processing_date": "2025-12-18T10:23:33.133281",
  "period": {
    "from_date": "2025-12-11T10:22:48.368843",
    "to_date": "2025-12-18T10:22:48.368862"
  },
  "items": [
    {
      "source_key": "bioworld_rss",
      "source_type": "rss",
      "title": "Novartis Advances CAR-T Cell Therapy for Multiple Myeloma",
      "summary": "Novartis announced positive results from its Phase III trial of CAR-T cell therapy targeting BCMA for relapsed/refractory multiple myeloma. The therapy showed significant improvement in progression-free survival compared to standard care.",
      "url": "https://example.com/novartis-cart-myeloma",
      "date": "2025-12-17T14:30:00Z",
      "companies_detected": [
        "Novartis"
      ],
      "molecules_detected": [],
      "technologies_detected": [
        "CAR-T cell therapy"
      ],
      "trademarks_detected": [],
      "indications_detected": [
        "relapsed/refractory multiple myeloma"
      ],
      "event_type": "clinical_update",
      "lai_relevance_score": 3,
      "anti_lai_detected": false,
      "pure_player_context": false,
      "domain_relevance": [
        {
          "domain_id": "tech_lai_ecosystem",
          "domain_type": "technology",
          "is_on_domain": false,
          "relevance_score": 0.2,
          "reason": "The article mentions CAR-T cell therapy, which is not a long-acting injectable technology."
        },
        {
          "domain_id": "regulatory_lai",
          "domain_type": "regulatory",
          "is_on_domain": false,
          "relevance_score": 0.1,
          "reason": "The article does not mention any regulatory approvals or guidelines."
        }
      ],
      "bedrock_matched_domains": [
        "tech_lai_ecosystem"
      ],
      "bedrock_domain_relevance": {
        "tech_lai_ecosystem": {
          "score": 0.6,
          "confidence": "medium",
          "reasoning": "The item is about a CAR-T cell therapy, which is a novel therapeutic technology, but not directly related to long-acting injectables or controlled release formulations that are the focus of this domain.",
          "matched_entities": {
            "companies": [],
            "molecules": [],
            "technologies": [
              "CAR-T cell therapy"
            ],
            "trademarks": []
          }
        },
        "regulatory_lai": {
          "score": 0.2,
          "confidence": "high",
          "reasoning": "The item is about clinical trial results for a novel therapy, but does not contain any information directly relevant to regulatory aspects of long-acting injectables.",
          "matched_entities": {
            "companies": [],
            "molecules": [],
            "technologies": [],
            "trademarks": []
          },
          "rejected_reason": "Score 0.2 < seuil 0.4"
        }
      },
      "matched_domains": [
        "regulatory_lai",
        "tech_lai_ecosystem"
      ],
      "deterministic_matched_domains": [
        "regulatory_lai"
      ],
      "matching_details": {},
      "score": 1.0,
      "scoring_mode": "balanced",
      "domain_priority": "high",
      "scoring_details": {
        "matched_domains": [
          "regulatory_lai",
          "tech_lai_ecosystem"
        ],
        "event_type": "clinical_update",
        "recency_days": 0
      }
    },
    {
      "source_key": "fierce_biotech_rss",
      "source_type": "rss",
      "title": "Roche Expands Oncology Pipeline with New ADC Technology",
      "summary": "Roche has acquired a new antibody-drug conjugate (ADC) platform technology that targets solid tumors and improves drug delivery while reducing toxicity. Initial studies focus on breast cancer and lung cancer applications.",
      "url": "https://example.com/roche-adc-technology",
      "date": "2025-12-17T10:15:00Z",
      "companies_detected": [
        "Roche"
      ],
      "molecules_detected": [],
      "technologies_detected": [
        "antibody-drug conjugate (ADC)"
      ],
      "trademarks_detected": [],
      "indications_detected": [
        "breast cancer",
        "lung cancer"
      ],
      "event_type": "corporate_move",
      "lai_relevance_score": 2,
      "anti_lai_detected": false,
      "pure_player_context": false,
      "domain_relevance": [
        {
          "domain_id": "tech_lai_ecosystem",
          "domain_type": "technology",
          "is_on_domain": false,
          "relevance_score": 0.2,
          "reason": "The article mentions an ADC technology, but it is not specifically related to long-acting injectable (LAI) technologies."
        },
        {
          "domain_id": "regulatory_lai",
          "domain_type": "regulatory",
          "is_on_domain": false,
          "relevance_score": 0.0,
          "reason": "The article does not mention any regulatory approvals, guidelines, or compliance matters related to LAI technologies."
        }
      ],
      "bedrock_matched_domains": [],
      "bedrock_domain_relevance": {
        "tech_lai_ecosystem": {
          "score": 0.2,
          "confidence": "medium",
          "reasoning": "The item mentions an antibody-drug conjugate (ADC) technology for targeted drug delivery, which is related to drug delivery systems. However, the key technologies and molecules in this domain are focused on long-acting injectables and sustained-release formulations, which are not directly relevant to the ADC technology mentioned.",
          "matched_entities": {
            "companies": [],
            "molecules": [],
            "technologies": [
              "antibody-drug conjugate (ADC)"
            ],
            "trademarks": []
          },
          "rejected_reason": "Score 0.2 < seuil 0.4"
        },
        "regulatory_lai": {
          "score": 0.1,
          "confidence": "high",
          "reasoning": "The item is about a new technology acquisition by Roche and does not mention any regulatory aspects or long-acting injectable products specifically. Therefore, it is not relevant to this regulatory domain focused on long-acting injectables.",
          "matched_entities": {
            "companies": [],
            "molecules": [],
            "technologies": [],
            "trademarks": []
          },
          "rejected_reason": "Score 0.1 < seuil 0.4"
        }
      },
      "matched_domains": [],
      "deterministic_matched_domains": [],
      "matching_details": {},
      "score": 1.08,
      "scoring_mode": "balanced",
      "domain_priority": "low",
      "scoring_details": {
        "matched_domains": [],
        "event_type": "corporate_move",
        "recency_days": 1
      }
    },
    {
      "source_key": "biocentury_rss",
      "source_type": "rss",
      "title": "FDA Approves First Gene Therapy for Duchenne Muscular Dystrophy",
      "summary": "The FDA has granted accelerated approval to Sarepta Therapeutics' gene therapy for Duchenne muscular dystrophy (DMD), which uses adeno-associated virus (AAV) vectors to deliver functional dystrophin genes to muscle cells. This marks a significant milestone in rare disease treatment.",
      "url": "https://example.com/fda-dmd-gene-therapy",
      "date": "2025-12-16T16:45:00Z",
      "companies_detected": [
        "Sarepta Therapeutics"
      ],
      "molecules_detected": [],
      "technologies_detected": [
        "adeno-associated virus (AAV) vectors",
        "gene therapy"
      ],
      "trademarks_detected": [],
      "indications_detected": [
        "Duchenne muscular dystrophy (DMD)"
      ],
      "event_type": "regulatory",
      "lai_relevance_score": 5,
      "anti_lai_detected": false,
      "pure_player_context": false,
      "domain_relevance": [
        {
          "domain_id": "tech_lai_ecosystem",
          "domain_type": "technology",
          "is_on_domain": false,
          "relevance_score": 0.3,
          "reason": "The article mentions gene therapy and AAV vectors, but does not explicitly discuss long-acting injectable technologies."
        },
        {
          "domain_id": "regulatory_lai",
          "domain_type": "regulatory",
          "is_on_domain": true,
          "relevance_score": 0.9,
          "reason": "The article discusses the FDA's accelerated approval of a gene therapy, which is a regulatory event."
        }
      ],
      "bedrock_matched_domains": [],
      "bedrock_domain_relevance": {
        "tech_lai_ecosystem": {
          "score": 0.2,
          "confidence": "high",
          "reasoning": "The item is about gene therapy using AAV vectors for Duchenne muscular dystrophy, which is not directly related to long-acting injectable technologies or the listed key entities for this domain.",
          "matched_entities": {
            "companies": [],
            "molecules": [],
            "technologies": [],
            "trademarks": []
          },
          "rejected_reason": "Score 0.2 < seuil 0.4"
        },
        "regulatory_lai": {
          "score": 0.1,
          "confidence": "high",
          "reasoning": "While the item mentions FDA approval, it is for a gene therapy unrelated to long-acting injectables or the listed key entities for this regulatory domain.",
          "matched_entities": {
            "companies": [],
            "molecules": [],
            "technologies": [],
            "trademarks": []
          },
          "rejected_reason": "Score 0.1 < seuil 0.4"
        }
      },
      "matched_domains": [],
      "deterministic_matched_domains": [],
      "matching_details": {},
      "score": 8.37,
      "scoring_mode": "balanced",
      "domain_priority": "low",
      "scoring_details": {
        "matched_domains": [],
        "event_type": "regulatory",
        "recency_days": 1
      }
    },
    {
      "source_key": "nature_biotech_rss",
      "source_type": "rss",
      "title": "CRISPR-Cas9 Breakthrough in Treating Sickle Cell Disease",
      "summary": "Researchers have successfully used CRISPR-Cas9 gene editing technology to treat sickle cell disease by editing patients' hematopoietic stem cells to produce functional hemoglobin. Clinical trials show sustained improvement in patients with severe sickle cell disease.",
      "url": "https://example.com/crispr-sickle-cell",
      "date": "2025-12-16T09:20:00Z",
      "companies_detected": [],
      "molecules_detected": [
        "hemoglobin"
      ],
      "technologies_detected": [
        "CRISPR-Cas9"
      ],
      "trademarks_detected": [],
      "indications_detected": [
        "sickle cell disease"
      ],
      "event_type": "clinical_update",
      "lai_relevance_score": 0,
      "anti_lai_detected": false,
      "pure_player_context": false,
      "domain_relevance": [
        {
          "domain_id": "tech_lai_ecosystem",
          "domain_type": "technology",
          "is_on_domain": false,
          "relevance_score": 0.2,
          "reason": "The article mentions CRISPR-Cas9 gene editing technology, but does not discuss long-acting injectable technologies."
        },
        {
          "domain_id": "regulatory_lai",
          "domain_type": "regulatory",
          "is_on_domain": false,
          "relevance_score": 0.1,
          "reason": "The article does not mention any regulatory approvals, guidelines, or compliance matters related to long-acting injectables."
        }
      ],
      "bedrock_matched_domains": [
        "tech_lai_ecosystem"
      ],
      "bedrock_domain_relevance": {
        "tech_lai_ecosystem": {
          "score": 0.7,
          "confidence": "high",
          "reasoning": "The item discusses the use of CRISPR-Cas9 gene editing technology, which is a novel and emerging technology relevant to the tech_lai_ecosystem domain. However, it does not directly mention any of the key companies, molecules, or trademarks listed for this domain.",
          "matched_entities": {
            "companies": [],
            "molecules": [],
            "technologies": [
              "CRISPR-Cas9"
            ],
            "trademarks": []
          }
        },
        "regulatory_lai": {
          "score": 0.2,
          "confidence": "high",
          "reasoning": "The item does not mention any regulatory aspects or approvals related to long-acting injectables or drug delivery systems, which is the focus of the regulatory_lai domain. The technology discussed (CRISPR-Cas9) is not directly relevant to this domain.",
          "matched_entities": {
            "companies": [],
            "molecules": [],
            "technologies": [],
            "trademarks": []
          },
          "rejected_reason": "Score 0.2 < seuil 0.4"
        }
      },
      "matched_domains": [
        "tech_lai_ecosystem"
      ],
      "deterministic_matched_domains": [],
      "matching_details": {},
      "score": 0.93,
      "scoring_mode": "balanced",
      "domain_priority": "high",
      "scoring_details": {
        "matched_domains": [
          "tech_lai_ecosystem"
        ],
        "event_type": "clinical_update",
        "recency_days": 2
      }
    },
    {
      "source_key": "endpoints_news_rss",
      "source_type": "rss",
      "title": "Gilead Sciences Reports Positive Data for HIV Prevention Drug",
      "summary": "Gilead Sciences announced positive Phase III results for its long-acting injectable HIV prevention drug that provides protection for up to 6 months with a single dose. The drug targets HIV reverse transcriptase and shows superior efficacy compared to daily oral PrEP.",
      "url": "https://example.com/gilead-hiv-prevention",
      "date": "2025-12-15T13:10:00Z",
      "companies_detected": [
        "Gilead Sciences"
      ],
      "molecules_detected": [],
      "technologies_detected": [
        "Long-Acting Injectable"
      ],
      "trademarks_detected": [],
      "indications_detected": [
        "HIV prevention"
      ],
      "event_type": "clinical_update",
      "lai_relevance_score": 10,
      "anti_lai_detected": false,
      "pure_player_context": false,
      "domain_relevance": [
        {
          "domain_id": "tech_lai_ecosystem",
          "domain_type": "technology",
          "is_on_domain": true,
          "relevance_score": 0.9,
          "reason": "The article discusses a long-acting injectable drug for HIV prevention, which is highly relevant to the LAI technology ecosystem."
        },
        {
          "domain_id": "regulatory_lai",
          "domain_type": "regulatory",
          "is_on_domain": false,
          "relevance_score": 0.2,
          "reason": "The article mentions positive Phase III results but does not provide specific regulatory details."
        }
      ],
      "bedrock_matched_domains": [
        "tech_lai_ecosystem"
      ],
      "bedrock_domain_relevance": {
        "tech_lai_ecosystem": {
          "score": 0.9,
          "confidence": "high",
          "reasoning": "The news item is highly relevant to the tech_lai_ecosystem domain as it reports on a long-acting injectable HIV prevention drug from Gilead Sciences, which aligns with the domain's focus on long-acting injectable technologies and drug delivery systems.",
          "matched_entities": {
            "companies": [
              "Gilead Sciences"
            ],
            "molecules": [],
            "technologies": [
              "Long-Acting Injectable"
            ],
            "trademarks": []
          }
        },
        "regulatory_lai": {
          "score": 0.2,
          "confidence": "medium",
          "reasoning": "The news item does not appear to be directly relevant to the regulatory_lai domain, as it does not mention any regulatory updates or approvals for long-acting injectable technologies. However, it may be of tangential interest as it involves a new long-acting injectable drug.",
          "matched_entities": {
            "companies": [],
            "molecules": [],
            "technologies": [
              "Long-Acting Injectable"
            ],
            "trademarks": []
          },
          "rejected_reason": "Score 0.2 < seuil 0.4"
        }
      },
      "matched_domains": [
        "regulatory_lai",
        "tech_lai_ecosystem"
      ],
      "deterministic_matched_domains": [
        "regulatory_lai"
      ],
      "matching_details": {},
      "score": 5.11,
      "scoring_mode": "balanced",
      "domain_priority": "high",
      "scoring_details": {
        "matched_domains": [
          "regulatory_lai",
          "tech_lai_ecosystem"
        ],
        "event_type": "clinical_update",
        "recency_days": 2
      }
    }
  ],
  "statistics": {
    "items_input": 5,
    "items_normalized": 5,
    "items_matched": 3,
    "items_scored": 5,
    "matching_rate": 60.0,
    "domain_statistics": {
      "regulatory_lai": 2,
      "tech_lai_ecosystem": 3
    }
  }
}